ADAMTS-5 inhibitors are primarily used in the field of medical research and therapeutic development, particularly for addressing conditions related to cartilage degradation. These inhibitors play a crucial role in targeting and blocking the activity of the ADAMTS-5 enzyme, which is known to break down aggrecan, a key component of cartilage. By inhibiting this enzyme, they help slow down or prevent cartilage destruction, making them a promising candidate for treating osteoarthritis and other joint-related diseases. Researchers are actively exploring their potential in developing drugs that can protect cartilage integrity and improve joint function in patients. Additionally, these inhibitors are studied for their role in understanding the mechanisms of extracellular matrix remodeling and tissue degeneration.